Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients

Virchows Archiv

Volumn 447, Issue 3, 2005, Pages 626-633

  Surowiak, Paweł ^a,b,c   Materna, Verena ^b   Kaplenko, Irina ^d   Spaczyński, Marek ^d   Dietel, Manfred ^b   Lage, Hermann ^b   Zabel, Maciej ^a,d  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Charité Campus Benjamin Franklin Medical Center   (Germany)

^c Wroclaw   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cisplatin; Glutathione S transferase pi; Metallothionein; Ovarian cancer

Indexed keywords

CISPLATIN; GLUTATHIONE TRANSFERASE; METALLOTHIONEIN; MONOCLONAL ANTIBODY; PARAFFIN;

ADULT; ARTICLE; CALCULATION; CANCER RELAPSE; DEATH; DISEASE COURSE; DISEASE PREDISPOSITION; DYNAMICS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LAPAROTOMY; MORTALITY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; METALLOTHIONEIN; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 24744452853     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-1228-0     Document Type: Article

References (32)

1. Averette HE, Hoskins W, Nguyen HN, Boike G, Flessa HC, Chmiel JS, Zuber K, Kamel LH, Winchester DPSO (1993) National survey of ovarian carcinoma. 1. A patient care evaluation study of the American College of Surgeons. Cancer 71:1629-1638
2. Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD (2003) Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 63:8097-8102
3. Dziȩgiel P, Forgacz J, Suder E, Surowiak P, Kornafel J, Zabel M (2003) Prognostic significance of metallothionein expression in correlation with Ki67 expression in adenocarcinomas of large intestine. Histol Histopathol 18:401-407
4. Goto S, Kamada K, Soh Y, Ihara Y, Kondo T (2002) Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 93:1047-1056
5. Hagrman D, Goodisman J, Dabrowiak JC, Souid AK (2003) Kinetic study on the relation of cisplatin with metallothionein. Drug Metab Dispos 31:916-923
6. Hamer DH (1986) Metallothionein. Annu Rev Biochem 55:913-951
7. Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M, Tachibana M, Nagasue N (1997) Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Lab Invest 54:342-347
8. Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, Nagasue N (1999) Metallothionein expression correlates with metastatic and proliferative potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81:712-720
9. Holschneider CH, Berek JS (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Sem Surg Oncol 19:3-10
10. Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, Shimizus M, Minanami H, Sakuragi N (2003) Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 13:776-784
11. Kagi JHR (1991) Overview of metallothionein. Methods Enzymol 205:613-626
12. Kaina B, Lohrer H, Karin M, Herrlich P (1990) Overexpressed human metallothionein IIA gene protects Chinese hamster ovary from killing by alkylating agents. Proc Natl Acad Sci U S A 87:2710-2714
13. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutat Res 478:23-43
14. Konishi I, Nanbu K, Mandai M, Tsuruta Y, Kataoka N, Nagata Y (1998) Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma. Gynecol Oncol 70:365-371
15. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijeng LH, Bokemeyer C (2003) Molecular determinants of treatment response in human germ-cell tumors. Clin Cancer Res 9:767-773
16. Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J (2000) Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 196:469-475
17. McCluggage WG, Strand K, Abdulkair A (2002) Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumours. Int J Gynecol Cancer 12:62-65
18. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, Sleijefer DT, Mulder NH (2000) Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85 (6):777-781
19. Miyatake K, Gemba K, Ueoka H, Nishii K, Kiura K, Tabata M, Shibayama T, Takigawa N, Kawaraya M, Tanimoto M (2003) Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer. Anticancer Res 23:2829-2836
20. Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, Mour S, Fujimoto Y, Matsuura H, Takai Y, Mori M (2000) Metallothionein immunoreactivity in head and neck carcinomas - special reference to clinical behaviors and chemotherapy responses. Anticancer Res 20:257-264
21. Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA, Montgomery EA, Bischoff EK, Cullen KJ (1996) Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2:1859-1865
22. Remmele W, Stegner HE (1987) Recommendation for uniform definition of an ImmunoReactive Score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138-140
23. Satoh T, Nishida M, Tsunoda H, Kubo T (2001) Expression of glutathione S-transferase pi (GST-pi) in human ovarian tumors. Eur J Obstet Gynecol Reprod Biol 96:202-208
24. Shimizu Y, Kamoi S, Amada S, Silverberg SG (1998) Toward the development of a universal grading system of ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82:893-901
25. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279
26. Siegsmund MJ, Marx C, Seeman O, Schummer B, Steidler A, Toktomambetova L, Kohrmann KU, Rassweiler J, Alken P (1999) Cisplatin-resistant bladder carcinoma cells: enhanced expression of metallothioneins. Urol Res 27:157-163
27. Siu LL, Banerjee D, Khurana RJ, Pan X, Pflueger R, Tannock IF (1998) The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 4:559-565
28. Surowiak P, Dziȩgiel P, Matkowski R, Kornafel J, Wojnar A, Zabel M (2002) Immunohistochemical evaluation of metallothionein (MT) expression in myoepithelial cells of ductal mammary carcinoma and its relation to survival time: analysis of 7 year-course of the disease. Folia Histochem Cytobiol 40:105-106
29. Toyoda H, Mizushima T, Satoh T, Iizuka N, Nomoto A, Chiba H, Mita M, Naganuma A, Himeno S, Imura N (2000) HeLa cell transformants overproducing mouse metallothionein show in vivo resistance to cis-platinum in nude mice. Jpn J Cancer Res 91:91-98
30. UICC (1997) TNM classification of malignant tumors. In: Sobin LH, Wittekind C (eds). Wiley-Liss, New York
31. Van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Wilemse PHB, Aalders JG, Vries EGE (1995) Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78
32. Wrigley E, Verpaget HW, Jayson GC, McGown AT (2000) Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 126:717-721